Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects With Moderate-to-Severe Atopic Dermatitis

NCT02525094 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT02525094
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02525094 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects With Moderate-to-Severe Atopic Dermatitis
Lead sponsor
MedImmune LLC
Phase
Phase 2
Overall status
Completed
Start date
August 15, 2015
Completion date
July 15, 2016
Enrollment
113 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis